Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 11/20 | 0.42 |
| ▸ | CCR6 | P51684 | 3/20 | 0.42 |
| ▸ | CCR7 | P32248 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.36 |
| ▸ | CCR4 | P51679 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407259 | 0.99 | CXCR2 (0.47) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL13407261 | 0.87 | CXCR2 (0.48) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL13405711 | 0.84 | CXCR2 (0.49) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL13344891 | 0.83 | CXCR2 (0.48) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL13208960 | 0.83 | CXCR2 (0.61) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12087138 | 0.83 | CXCR2 (0.62) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL13948496 | 0.82 | CXCR2 (0.50) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL14639803 | 0.82 | CXCR2 (0.46) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL13207062 | 0.81 | CXCR2 (0.48) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12779865 | 0.80 | CXCR2 (0.47) | CXCR2CXCR1CCR6CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | CXCR2 6/4885CXCR1 1/4885CCR6 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.